Shows
The Top LineForging the future of cell therapy: Bayer and BlueRock’s unique journey (Sponsored)In this episode of The Top Line, Fierce Biotech’s Chris Hayden sat down with Dr. Juergen Eckhardt of Bayer and Dr. Seth Ettenberg of BlueRock Therapeutics to discuss an innovative partnership that’s reshaping how big pharma teams up with biotech startups. BlueRock, a wholly owned subsidiary of Bayer, operates with the independence of a small biotech while benefiting from Bayer’s global reach and infrastructure. The “arm’s-length” model gives BlueRock the agility to innovate while leveraging Bayer’s resources in manufacturing, clinical trials and commercialization. The collaboration has already led to major milestones, in...2025-06-0234 min
Just One Question: Public Speaking PodcastJOQ S3 E6: Biotech expert Seth and Nick discuss revolutionary regenerative medicine treatmentsSeth Ettenberg and Nick discuss how technology is used to develop regenerative medicine for conditions such as Parkinson's disease and Alzheimer's disease.Seth Ettenberg is CEO and President of BlueRock Therapeutics, a wholly owned subsidiary of Bayer. He’s a biotech entrepreneur, on the cutting edge of something called regenerative medicine.2023-10-2709 min
Cell & Gene: The PodcastThe Future of iPSCs with BlueRock Therapeutics' CEO Seth EttenbergWe love to hear from our listeners. Send us a message.BlueRock Therapeutics' President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company's Phase 1 Clinical Trial for Advanced Parkinson’s Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as the major regulatory challenges that the field faces for their clinical use. We also cover how far iPSCs have come and what future progress may entail.Subscribe to the podcast!Apple | Spotify | ...2022-12-0828 min